Advanced in silico approaches in antiviral research

Antiviral Chemistry and Chemotherapy

Volumn 20, Issue 4, 2010, Pages 147-151

  Zonta, Nicola ^a   Coluccia, Antonio ^a   Brancale, Andrea ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER AIDED DESIGN; COMPUTER MODEL; DRUG DESIGN; DRUG RESEARCH; DRUG SCREENING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SIMULATION;

ANTIVIRAL AGENTS; COMPUTER-AIDED DESIGN; DRUG DESIGN; MOLECULAR DYNAMICS SIMULATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949679042     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1500     Document Type: Review

References (39)

1. Jorgensen WL. Efficient drug lead discovery and optimization. Acc Chem Res 2009; 42:724-733.
2. Zonta N, Grimstead IJ, Avis NJ, Brancale A. Accessible haptic technology for drug design applications. J Mol Model 2009; 15:193-196.
3. Hutter MC. In silico prediction of drug properties. Curr Med Chem 2009; 16:189-202.
4. Zhang J, Li W, Wang J, et al. Protein folding simulations: from coarse-grained model to all-atom model. IUBMB Life 2009; 61:627-643.
5. Congreve M, Murray CW, Blundell TL. Structural biology and drug discovery. Drug Discov Today 2005; 10:895-907.
6. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363:418-423.
7. Palese P, Schulman JL. Inhibitors of viral neuraminidase as potential antiviral drugs. In Oxford JS (Editor). Chemoprophylaxix and virus infection of the upper respiratory tract. Vol. 1. Cleveland: CRC Press 1997; pp. 189-205.
8. Varghese JN, Colman PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution. Nature 1983; 303:35-40.
9. Varghese JN, Colman PM. Structural basis of antigenic variation: Studies of influenza virus neuraminidase. J Mol Biol 1991; 221:473-486.
10. Nandi T. Proposed lead molecules against hemagglutinin of avian influenza virus (H5N1). Bioinformation 2008; 2:240-244.
11. Zhou Z, Khaliq M, Suk JE, et al. Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein. ACS Chem Biol 2008; 3:765-775.
12. Cheng LS, Amaro RE, Xu D, et al. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J Med Chem 2008; 51:3878-3894.
13. Pérez-Nueno VI, Ritchie DW, Rabal O, et al. Comparison of ligand-based and receptor-based virtual screening of HIV entry inhibitors for the CXCR4 and CCR5 receptors using 3D ligand shape matching and ligand-receptor docking. J Chem Inf Model 2008; 48:509-533.
14. Seifert MHJ, Schmitt F, Herz T, Kramer B. ProPose: a docking engine based on a fully configurable protein-ligand interaction model. J Mol Model 2004; 10:342-357.
15. Seifert MHJ. ProPose: Steered virtual screening by simultaneous protein-ligand docking and ligand-ligand alignment. J Chem Inf Model 2005; 45:449-460.
16. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004; 3:301-317.
17. Trosset JY, Dalvit C, Knapp S, et al. Inhibition of protein-protein interactions: the discovery of drug-like catenin inhibitors by combining virtual and biophysical screening. Proteins 2006; 64:60-67.
18. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science 1995; 267:383-386.
19. Betzi S, Restouin A, Opi S, et al. Protein-protein interaction inhibition (2P2I) combining high throughput and virtual screening: application to the HIV-1 nef protein. Proc Natl Acad Sci U S A 2007; 104:19256-19261.
20. De Luca L, Barreca ML, Ferro S. Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. ChemMedChem 2009; 4:1311-1316.
21. Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 2005; 4:649-663.
22. Kandil S, Biondaro S, Vlachakis D, et al. Discovery of a novel HCV helicase inhibitor by a de novo drug design approach. Bioorg Med Chem Lett 2009; 19:2935-2937.
23. Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998; 27:249-284.
24. Gehlhaar DK, Moerder KE, Zichi D, Sherman CJ, Ogden RC, Freer ST. De novo design of enzyme inhibitors by Monte Carlo ligand generation. J Med Chem 1995; 38:466-472.
25. Lebon F, Ledecq M. Approaches to the design of effective HIV-1 protease inhibitors. Curr Med Chem 2000; 7:455-477.
26. Karplus M, McCammon JA. Molecular dynamics simulations of biomolecules. Nat Struct Biol 2002; 9:646-652.
27. Hensen C, Hermann JC, Nam K, et al. A combined QM/MM approach to protein-ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors. J Med Chem 2004; 47:6673-6680.
28. Gedeck P, Lewis RA. Exploiting QSAR models in lead optimization. Curr Opin Drug Discov Devel 2008; 11:569-575.
29. Vedani A, Dobler M. Multidimensional QSAR: moving from three- to five-dimensional concepts. Quant Struct Act Relat 2002; 21:383-391.
30. Hopfinger AJ, Wang S, Tokarski JS, et al. Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J Am Chem Soc 1997; 119:10509-10524.
31. Bak A, Polanski J. A 4-D QSAR study on anti-HIV HEPT analogues. Bioorg Med Chem 2006; 14:273-279.
32. Santos-Filho OA, Hopfinger AJ. The 4D-QSAR paradigm: application to a novel set of non-peptidic HIV protease inhibitors. Quant Struct Act Relat 2002; 21:369-381.
33. Putta S, Beroza P. Shapes of things: computer modeling of molecular shape in drug discovery. Curr Top Med Chem 2007; 7:1514-1524.
34. Mestres J, Rohrer DC, Maggiora GM. A molecular-fieldbased similarity study of non-nucleoside HIV-1 reverse transcriptase inhibitors. J Comput Aided Mol Des 1999; 13:79-93.
35. Zauhar RJ, Moyna G, Tian LF, Li ZJ, Welsh WJ. Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design. J Med Chem 2003; 46:5674-5690.
36. Ballester PJ, Finn PW, Richards WG. Ultrafast shape recognition: evaluating a new ligand-based virtual screening technology. J Mol Graph Model 2009; 27:836-845.
37. Irwin JJ, Shoichet BK. ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005; 45:177-182.
38. Coutard B, Gorbalenya AE, Snijder EJ, et al. The VIZIER project: preparedness against pathogenic RNA viruses. Antiviral Res 2008; 78:37-46.
39. The Protein Data Bank. (Updated 26 January 2010. Accessed 28 January 2010.) Available from http://www.pdb.org